Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Ins & Outs of Patient Assistance Programs

Samantha C. Shapiro, MD  |  March 3, 2022

Given the profound impact biologic drugs have on disease control, quality of life and potential reduction of long-term disability in patients with rheumatic disease, the ACR’s Committee on Rheumatologic Care released a position statement on patient access to biologics in August 2021. It states: “Patients should have affordable access to biologic therapy without undue delay.”1 

As practicing rheumatology providers, I know we all agree with that statement. However, the hefty price tags of biologic therapies create a plethora of access issues that burden providers and delay care for our patients—even those who have health insurance.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What about the 8.6% of American residents, about 28 million people, who don’t have health insurance?2 And what about the millions more who are underinsured? These people are not immune to autoimmune disease. They often delay their own care due to out-of-pocket costs they simply cannot afford, so by the time they’re in your office, their disease is likely to be severe.3  

During the three years I spent caring for patients with rheumatic disease at a federally qualified health center in Austin, Texas, 73% of the patients I cared for were uninsured. Thirty-nine percent of rheumatoid arthritis patients already had erosive disease at their first visit with me.4 Based on this experience, I can share insights into how to obtain free biologics for uninsured patients via patient assistance programs (PAPs).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What Is a PAP?

Sponsored by drug companies, PAPs provide qualifying, uninsured or underinsured, low-income patients with free medications. Although no program is perfect and applications can be tedious (especially for non-English-speaking patients), PAPs are often the only means by which patients can obtain the biologic therapies they need.

In some ways, obtaining biologics via a PAP can be simpler than obtaining them for patients who have health insurance. Formulary restrictions, prior authorization headaches and step therapy protocols don’t apply to PAPs. Simply choose the therapy you feel is best for the patient and complete the application. If all required documents are received as quickly as possible, the patient could expect to be approved for a year of free drugs within a matter of weeks. Tips on how to streamline the process are discussed below.  

Does My Patient Qualify?

In general, for a patient to qualify for a free medication through a PAP, pharmaceutical companies request proof of the following:

  • U.S. residency—of note, immigration or citizenship documents are not required for most applications;
  • Lack of health insurance or lack of adequate coverage by current plan—for the uninsured, fulfilling this requirement is as simple as checking a box to that effect. For the underinsured, additional documentation of the coverage gap is requested; and
  • Income below a designated threshold—Drug companies accept a wide array of proof-of-income documents, such as tax documents, pay stubs or a letter of declaration from the patient or responsible party stating they earn X amount monthly. Income eligibility thresholds are specific to each program.

Practical Tips

After a year of struggling to help hundreds of patients obtain medications via PAPs, my partner and I spent a day calling every rheumatology drug PAP we could think of (see Figure 1). Here, I share practical tips from that reconnaissance work:

  1. Apply online when available. Turnaround time is substantially quicker—weeks rather than months—for online applications than for mailed or faxed applications.
  2. Call the drug company directly with questions. PAP staff are responsive and great at troubleshooting. Calling is easier than finding answers on drug company websites, especially because PAP information is often buried beneath multiple clicks.
  3. Involve one of your team members to follow up with the patient and assist with the application process as needed. This is especially important for non-English-speaking patients because PAP phone services all start with prompts in English.
  4. Send in the provider part of the PAP application at the time of visit. Nearly all applications require a signed form from the prescriber as part of the application. These can be found on PAP websites.
  5. Encourage the patient to follow up with the drug company every two weeks to confirm receipt of all required documents and to check on status. Drugs won’t be approved if any part of the application is missing, but companies don’t typically notify patients about missing paperwork. Delays in approval notification are also common, and the patient typically needs to call to arrange delivery of the first shipment. It’s frustrating to find out a free drug supply has been approved for months, unbeknownst to the patient or provider.
  6. Remind the patient to call the drug company directly to set up refill deliveries. Some companies allow patients to sign up to receive text message reminders about refills.
  7. Plan ahead. Most drug companies approve free drug supplies for one year, although some may approve the drug for up to three years. If therapy is to be continued via a PAP, the patient must reapply one to three months before their approval lapses.

Figure 1. PAP phone numbers as of January 2022.

Patient Assistance Program

Medications Phone number
My AbbVie Assist

adalimumab (Humira)

upadacitinib (Rinvoq)

risankizumab (Skyrizi)

(800) 222-6885
Amgen Safety Net Foundation

etanercept (Enbrel)

apremilast (Otezla)

(888) 762-6436
Pfizer PAP (Xelsource)

tofacitinib (Xeljanz)

(844) 935-5269
Novartis Patient Assistance Foundation

secukinumab (Cosentyx)

mycophenolate sodium (Myfortic)

canakinumab (Ilaris)

(800) 277-2254
J&J Patient Assistance Foundation

ustekinumab (Stelara)

guselkumab (Tremfya)

golimumab (Simponi)

infliximab (Remicade)

(800) 652-6227
Bristol Meyers Squibb Patient Assistance Foundation

abatacept (Orencia)

(800) 736-0003
Genentech Patient Foundation

tocilizumab (Actemra)

rituximab (Rituxan)

(888) 941-3331
Genentech Access to Care Foundation

mycophenolate mofetil (CellCept)

(888) 754-7651
Lilly Cares

ixekizumab (Taltz)

baricitinib (Olumiant)

(800) 545-6962
GSK Benlysta Cares

belimumab (Benlysta)

(877) 423-6597
Takeda Help at Hand

colchicine (Colcrys)

(800) 830-9159
Sobi Kineret on Track

anakinra (Kineret)

(866) 547-0644
Horizon Patient Services

pegloticase (Krystexxa)

(877) 633-9521
UCB Cares

certolizumab pegol (Cimzia)

(877) 785-8906

Takeaways

PAPs can help uninsured patients obtain access to biologic medications. Calling PAP phone numbers is refreshingly easy, and the staff are helpful. Some patients, especially those who don’t speak English, will benefit from your team’s help to complete the application process. Although the PAP process is imperfect and requires extra work on the provider’s part, the benefit to uninsured patients with rheumatic disease is priceless. Literally.


Samantha C. Shapiro, MD, is an academic rheumatologist and an affiliate faculty member of the Dell Medical School at the University of Texas at Austin. She received her training in internal medicine and rheumatology at Johns Hopkins University, Baltimore. She is also a member of the ACR Insurance Subcommittee.

References

  1. Position statement on access to biologics. American College of Rheumatology. 2021 Aug.
  2. Keisler-Starkey K and Bunch LN. Health insurance coverage in the United States: 2020. United States Census Bureau. 2021 Sept 14.
  3. Addington WW. No health insurance? It’s enough to make you sick—Scientific research linking the lack of health coverage to poor health. American College of Physicians policy statement. 1999.
  4. Patel V, Patel R, Hackshaw K. Rheumatology care for the underserved in Central Texas [abstract]. Arthritis Rheumatol. 2021 Oct;73(suppl 10).

Page: 1 2 3 | Multi-Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:biologic therapiesdrug costsfederally qualified health centerpatient assistance programs (PAP)patient careuninsured Americans

Related Articles

    Combine With Medicare Part D to Help Patients Afford Prescriptions

    February 1, 2007

    According to the 2003 U.S. Census, 29 million people in the United States make less than 200% of the federal poverty level and have no health insurance. Many persons have difficulty affording prescribed medications. In addition to Medicare Part D, there are more than 350 public and private patient assistance programs, including programs by pharmaceutical companies, that help patients pay for prescriptions.

    Colcrys Approval Triggers Questions

    May 1, 2010

    Some rheumatologists question the depth of research and the approval’s implications for patient access

    Drug Assistance Programs Offer Little Charity to Uninsured

    August 7, 2019

    (Reuters Health)—Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that covers most the cost for their medications, a U.S. study suggests. Researchers examined data on the six largest independent charities offering patient assistance programs through 274 different disease-specific programs. These programs had total revenue ranging…

    U.S. Uninsured Rate Up by Most in Nearly a Decade

    January 16, 2018

    WASHINGTON (Reuters)—The number of Americans without health insurance rose by 3.2 million people between 2016 and 2017, or 1.3% points to 12.2%, according to a Gallup poll released on Tuesday, the biggest jump in the uninsured rate in nearly a decade.1 Several factors likely contributed to the jump, Gallup said, including attempts by Republicans, who…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences